Insider Activity Monitoring: Catalyst Pharmaceuticals Inc. (CPRX)

0
17

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) saw a downside of -29.04% to close Monday at $14.76 after subtracting -$6.04 on the day. The 5-day average trading volume is 5,153,940 shares of the company’s common stock. It has gained $21.53 in the past week and touched a new high 1 time within the past 5 days. An average of 2,826,870 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,781,994.

CPRX’s 1-month performance is -20.65% or -$4.25 on its low of $13.30 reached on 01/23/23. The company’s shares have touched a 52-week low of $5.24 and high of $22.11, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, CPRX has lost -20.65% or -$3.84 and has reached a new high 6 times. However, the current price is down -33.24% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Insider Transactions

CPRX stock investors last saw insider trading activity on Dec 06.INGENITO GARY (Chief Medical Officer) most recently sold 5,918 shares at $16.85 per share on Dec 06. This transaction cost the insider $99,718. Director, COELHO PHILIP H, sold 9,999 shares at a price of $17.45 on Nov 23. Then, on Nov 23, Chief Operating Officer Miller Steve sold 20,000 shares at a price of $17.34 per share. This transaction amounted to $346,740.

Valuation Metrics

CPRX stock has a beta of 1.26. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 7.80 while the price-to-book (PB) in the most recent quarter is 5.66.

Catalyst Pharmaceuticals Inc.’s quick ratio for the period ended September 29 was 6.00, with the current ratio over the same period at 6.20. In terms of profitability, the gross margin trailing 12 months is 84.10%. The firm’s gross profit as reported stood at $118.95 million against revenue of $140.83 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 54.59% to $22.75 million, while revenue of $21.62 million was 4.97% off the previous quarter. Analysts expected CPRX to announce $0.19 per share in earnings in its latest quarter, but it posted $0.2, representing a 5.30% surprise. EBITDA for the quarter stood at more than $25.66 million. CPRX stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 63.07 million, with total debt at $3.97 million. Shareholders hold equity totaling $104.07 million.

Let’s look briefly at Catalyst Pharmaceuticals Inc. (CPRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 25.60% to suggest the stock is trending oversold, with historical volatility in this time period at 180.32%.

The stock’s 5-day moving average is $19.28, reflecting a -29.88% or -$6.29 change from its current price. CPRX is currently trading -24.31% above its 20-day SMA, +4.53% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -3.72% and SMA200 by+76.56%.

Stochastic %K and %D was 47.25% and 55.18% and the average true range (ATR) pointed at 1.79. The RSI (14) points at 33.14%, while the 14-day stochastic is at 16.57% with the period’s ATR at 1.53. The stock’s 9-day MACD Oscillator is pointing at -1.16 and -0.82 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), ROTH Capital downgraded it to a Neutral rating. They previously had a Buy rating on the stock. Analysts offering their rating for CPRX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CPRX as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.

What is CPRX’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $15.50 and a high of $24.00, with their median price target at $22.00. Looking at these predictions, the average price target given by analysts is for Catalyst Pharmaceuticals Inc. (CPRX) stock is $20.70.

LEAVE A REPLY

Please enter your comment!
Please enter your name here